(Q34357389)

1 August 2017

0 references

0 references

Metformin and breast cancer risk: a meta-analysis and critical literature review (English)

1 reference

1 August 2017

0 references

1 reference

1 reference

5

Rowan T Chlebowski

1 reference

1 August 2017

Nananda F Col

1

1 reference

1 August 2017

Leslie Ochs

series ordinal

2

1 reference

1 August 2017

Vicky Springmann

series ordinal

3

1 reference

1 August 2017

Aaron K Aragaki

series ordinal

4

1 reference

1 August 2017

language of work or name

English

0 references

publication date

31 July 2012

1 reference

Breast Cancer Research and Treatment

1 August 2017

published in

1 reference

1 August 2017

volume

135

1 reference

1 August 2017

issue

3

1 reference

1 August 2017

page(s)

639-646

1 reference

https://scigraph.springernature.com/pub.10.1007/s10549-012-2170-x

1 August 2017

exact match

0 references

cites work

Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2170-X

Diabetes mellitus and breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2170-X

Diabetes mellitus and risk of breast cancer: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2170-X

Medical management of hyperglycaemia in type 2 diabetes mellitus: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2170-X

Insulin-lowering effects of metformin in women with early breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2170-X

Metformin: a therapeutic opportunity in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2170-X

Role of AMP-activated protein kinase in mechanism of metformin action

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2170-X

Metformin and cancer risk in diabetic patients: a systematic review and meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2170-X

The influence of glucose-lowering therapies on cancer risk in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2170-X

New users of metformin are at low risk of incident cancer: a cohort study among people with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2170-X

Long-term metformin use is associated with decreased risk of breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2170-X

Cancer risk in diabetic patients treated with metformin: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2170-X

Diabetes mellitus and breast cancer outcomes: a systematic review and meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2170-X

GRADE guidelines: 4. Rating the quality of evidence--study limitations (risk of bias)

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2170-X

Metformin and cancer occurrence in insulin-treated type 2 diabetic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2170-X

Low HDL cholesterol, metformin use, and cancer risk in type 2 diabetes: the Hong Kong Diabetes Registry.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2170-X

Does use of metformin protect against cancer in Type 2 diabetes mellitus?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2170-X

Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2170-X

Experience of malignancies with oral glucose-lowering drugs in the randomised controlled ADOPT (A Diabetes Outcome Progression Trial) and RECORD (Rosiglitazone Evaluated for Cardiovascular Outcomes and Regulation of Glycaemia in Diabetes) clinical t

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2170-X

Further exploration of the relationship between insulin glargine and incident cancer: a retrospective cohort study of older Medicare patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2170-X

Effect of metformin on survival outcomes in diabetic patients with triple receptor-negative breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2170-X

Glucose-lowering agents and the patterns of risk for cancer: a study with the General Practice Research Database and secondary care data.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2170-X

Metformin and incident breast cancer among diabetic women: a population-based case-control study in Denmark

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2170-X

Lower risk of cancer in patients on metformin in comparison with those on sulfonylurea derivatives: results from a large population-based follow-up study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2170-X

Metformin in cancer: translational challenges

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2170-X

Ki67 in breast cancer: prognostic and predictive potential

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2170-X

Metformin and pathologic complete responses to neoadjuvant chemotherapy in diabetic patients with breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2170-X

Metformin inhibits breast cancer cell growth, colony formation and induces cell cycle arrest in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2170-X

Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2170-X

Management of type 2 diabetes: new and future developments in treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2170-X

Meta-analysis of Observational Studies in Epidemiology: A Proposal for Reporting

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2170-X

Evaluation of metformin in early breast cancer: a modification of the traditional paradigm for clinical testing of anti-cancer agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2170-X

10.1007/S10549-012-2170-X

21 January 2018

Identifiers

DOI

1 reference

Dimensions Publication ID

1 August 2017

1022720204

0 references

1 reference